Collaboration promises new clinical diagnostics
Agilent Technologies and Applied Proteomics has agreed to collaborate on highly multiplexed protein assays and workflow solutions for multiple reaction monitoring through mass spectrometry.
Applied Proteomics will use Agilent 6490 Triple Quadrupole MS/MS, 1290 Infinity LC, RapidFire 360 MS system and Bravo liquid-handling technologies to optimise the throughput of highly multiplexed proteomic assays.
Multiple reaction monitoring, a highly specific and sensitive mass-spectrometry technique, can detect and quantify analytes from plasma, serum and other biological samples. A multiplex assay can simultaneously measure multiple analytes, such as proteins, peptides, metabolites and lipids.
'The ability to quickly and accurately measure, monitor and analyse a large number of protein biomarkers in a single test has important applications for understanding human diseases and developing new clinical diagnostics,' said John Blume, chief science officer of Applied Proteomics.
'Agilent’s innovation in mass spectrometry is an important part of this collaboration as we work together to expand the capabilities of multiplex protein assays.'